CRL-AIMM- Central Research Laboratory- Adichunchangari institute of Molecular Medicine
ADICHUNCHANAGIRI INSTITUTE FOR MOLECULAR MEDICINE
AIMS –CENTRAL RESEARCH LABORATORY
Adichunchanagiri Institute for Molecular Medicine (AIMM) functioning along with AIMS – Central Research Laboratory. The research program from 1998 till April 2017 has been mainly centered around dietary antioxidants in prevention of oxidative stress, which is now recognized as a possible etiological factor for many diseases like Cancer, arthritis, cataract, heart ailments, snake bite, malaria, bacterial, fungal infections. It is a matter of pride that, the institute have been funded by National Cancer Institute of National Institute of Health towards developing the Turmeric peptide as a possible cancer preventive biomolecule under RAPID program. It is a matter of very high satisfaction that, our two publications have been cited as the top entities as most read, downloaded and cited among 2000 publications.
In brief, we have discovered very potent antioxidant from Turmeric with a molecular weight of 8 kDa which we have named as “Arishinin”. This discovery is patented at the Chennai patent office for Indian patent and also has been awarded US patent (US 8,389,677B2).
The institute was successful in identifying a death factor released by fuel, cigarette or organic smoke called as SCID (Smoke Condensate Induced Death factor). We have also reported death factors released from snake venom called as PID-15 (Phospholipase Induced Death factor -15). The above two factors appears to be a death signaling peptides. Other than the above, we have purified a 14 kDa protein from Turmeric and also sequenced the above and registered in Swiss Uniprot (Uniprot P85278).
Now, the laboratory is mainly focusing on synthesis and developing new chemical entities/ drug like small molecules in the field of Cancer, Leishmaniasis and Diabetes. The drug discovery involves the identification of lead molecules, screening hits, and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability and bioavailability.
With the interest of above said field, we are actively involved in synthesizing heterocyclic compounds to target proteins involved in DNA repair, cancer metastasis etc. Apart from above said disease filed, we are also in thrust of identifying small molecules and biomarkers for the cardiovascular diseases and diabetes.
DETAILS OF STAFF
|Sl No.||NAME & DESIGNATION||QUALIFICATION|
|1||Dr. SHOBITH RANGAPPA (DIRECTOR)||M.Sc. Ph.D.|
|2||Ms. PARIMALA HANUMESH (SCIENTIFIC OFFICER)||MS CHEMISTRY|
|3||Dr. DINESHA R (SCIENTIFIC OFFICER)||M.Sc. Ph.D.|
|4||Dr. THAMMANNAGOWDA SS (SCIENTIFIC OFFICER)||M.Sc. Ph.D.|
|5||Dr. ANANDA H (SCIENTIFIC OFFICER)||M.Sc. Ph.D.|
|6||Dr. SUDHANVA MS (SCIENTIFIC OFFICER)||M.Sc. Ph.D.|
Ongoing Research activities:
3 months work plan
Local cancer survey had begun to find out the major predominant cancer types.
Compound libraries are screened using Molecular modelling to find out a lead molecule targeting cell cycle regulatory proteins and proteins involved in cell migration.
Collaborations with Prof K. S. Rangappa and Dr.Peter J Houghton we are synthesising novel small molecules mainly Thiazolidinones based compounds which targets cell cycle regulatory proteins and proteins involved in cell migration.
We synthesised nearly 50 Novel molecules and they are ready for NMR and Mass detection and after complete purification of the regioselective molecules screening process will begins using cell based assays.
Future work plan
After the complete purification of compounds, screening process will begin using primary cancer cell lines mainly apoptotic assays, cell survival assays and cell cycle analysis to find out most potent molecule.
Once the potent molecule is indentified further cell based assays like cell migration assay, Proliferation assay, and Mitochondrial membrane potential assays will be carried.
Later toxicity studies will begins to find out the toxic effect of synthesised molecules on mammalian cells using mice models.
In future, planning to establish gene expression studies to find out aberrant expression of genes in cancer cell and to find out a novel biomarker for detection of lung and cervical cancer.
|Bench Top Centrifuge|
|Biosafety cabinet (class II Type A2)|
|Chemi Doc Imaging System|
|CO2 Incubator (Air Jacketed)|
|DIGI 200 Digital power supply with digital timer|
|Dry water bath|
|ECOBLOT mini electro blotting wet transfer systems-Mini|
|ECODNA systems- Horizontal gel Electrophoresis systems|
|ECOSDS mini dual systems Gel size 2|
|Electronic Weighing Balance|
|Fluorescent Inverted Microscope (All accessories)|
|High throughput screening facility|
|HVAC Systems installation|
|Lab Refrigerator (upright)|
|Micro centrifuge- 6000rpm|
|Micro plate Reader|
|Orbital shaker and incubator|
|Pharmaceutical Refrigerator (deli fridge)|
|Refrigerated centrifuge (floor model and bench model)|
|Refrigerated shaking incubator|
|Roller drum yeast culture tube rotator|
|RT – PCR|
|Sonicator Probe Type|
|Speed Vaccuum concentrator|
|TABLETOP Micro centrifuge- 6000rpm|
|Thermal Cycler (PCR)|
|Vertical Electrophoresis Unit with Power pack|
|Water Purification System|
|Western blotting semi-dry Transfer System|